Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.

MLA

Leiter, Lawrence A., et al. “Cardiovascular Risk Reduction with Once-Weekly Semaglutide in Subjects with Type 2 Diabetes: A Post Hoc Analysis of Gender, Age, and Baseline CV Risk Profile in the SUSTAIN 6 Trial.” Cardiovascular Diabetology, vol. 18, no. 1, June 2019, p. 73. EBSCOhost, https://doi.org/10.1186/s12933-019-0871-8.

APA

Leiter, L. A., Bain, S. C., Hramiak, I., Jódar, E., Madsbad, S., Gondolf, T., Hansen, T., Holst, I., & Lingvay, I. (2019). Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovascular Diabetology, 18(1), 73. https://doi.org/10.1186/s12933-019-0871-8

Chicago

Leiter, Lawrence A, Stephen C Bain, Irene Hramiak, Esteban Jódar, Sten Madsbad, Theis Gondolf, Thomas Hansen, Ingrid Holst, and Ildiko Lingvay. 2019. “Cardiovascular Risk Reduction with Once-Weekly Semaglutide in Subjects with Type 2 Diabetes: A Post Hoc Analysis of Gender, Age, and Baseline CV Risk Profile in the SUSTAIN 6 Trial.” Cardiovascular Diabetology 18 (1): 73. doi:10.1186/s12933-019-0871-8.